AMENDMENTS TO THE CLAIMS

1. (currently amended) A lipid-drug complex for subcutaneous administration comprising:

at least one lipid molecule;, and

at least one drug molecule having low aqueous solubility within a neutral pH range; and

wherein the at least one drug molecule substantially dissociates from the lipid-drug complex within a pH range from about pH 5.0 to about pH 5.5.

2. (original) The lipid-drug complex of Claim 1, wherein the neutral pH range includes a range near pH 5.0 to about pH 8.

3. (original) The lipid-drug complex of Claim 1, wherein the lipid and drug molecules are associated as a complex at a molar ratio of lipid-to-drug that is within a range of about 3:1 to about 100:1.

4. Cancelled.

5. (original) The lipid-drug complex of Claim 1, wherein the lipid-drug complex is a liposome.

6. (original) The lipid-drug complex of Claim 1, wherein the liposome is a unilamellar liposome.

7. (original) The lipid-drug complex of Claim 1, wherein the drug is an anti-viral drug.

8. (original) The lipid-drug complex of Claim 1, wherein the drug is an anti-HIV drug.

9. (original) The lipid-drug complex of Claim 1, wherein the drug is indinavir, saquinavir, nelfinavir, or tenofovir disoproxil fumarate.

10 – 14 Withdrawn

15. (original) The lipid-drug complex of Claim 1, wherein the lipid includes one or more of phospholipids, sphingolipids, cardiolipins, spingomyelin, glycolipids, gangliosides, cerebrosides, cholesterol, fatty acids, PEG derivatized lipids, monoglycerides, diglycerides, triglycerides.

16. (original) The lipid-drug complex of Claim 1, wherein the lipid-drug complex is about 30 to about 150 nanometers in diameter.

17. (original) The lipid-drug complex of Claim 1, wherein the lipid-drug complex is about 50 to about 80 nanometers in diameter.

18. – 45 Cancelled